Ackman's now in control with a new board and new CEO. The other day, VRX fell to 28, but that lasted a nanosecond and it bounced right back up over 30. I think it's a steal down here at 30. In fact the entire biotech sector is now looking cheap.....relative to 6 months ago.
Biotech has been in a bull market for years now....I wouldn't doubt the next bear market dropping the biotech sector by at least 50%
do you want to deal with 30 billion in debt? would someone explain why the co. is not in a death spiral?
Debt-Schmedt.....Doesn't matter. I think Uber is about 30 billion in debt and they're going IPO soon. Debt is cheap.
My bad...I was thinking of Martin Shkreli of KaleBios infamy. Still....I heard the former CEO was not that good.
One thing is for sure, VRX is a bad short. Debt and non-GAAP metrics such as "cash EPS" are things that other stocks in the industry also have but they are at a much bigger valuations. If shorts are right on VRX, they make 100% but if they are wrong, they lose 100-300%.